GORDON, K.; WARREN, R.; GOTTLIEB, A.; BLAUVELT, A.; THAÇI, D.; POULIN, Y.; BOEHNLEIN, M.; BROCK, F.; ARENDT, C.; REICH, K. Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT). SKIN The Journal of Cutaneous Medicine, v. 4, n. 6, p. s81, 27 Oct. 2020.